Mammary Ductal Carcinoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mammary Ductal Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions.
Ductal carcinoma is a type of breast cancer that occurs in the milk ducts and moves into nearby tissues. There are two types of ductal carcinoma, invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS). If the abnormal cancer cells are seen inside the milk ducts, then it is DCIS. DCIS is also known as intraductal carcinoma or non-invasive ductal carcinoma. If the cancer occurs in the lining of milk ducts and invades the breast tissue beyond duct walls, then it is IDC. IDC is also known as infiltrating ductal carcinoma or ductal adenocarcinoma.
The Mammary Ductal Carcinoma drugs in development market research report provide comprehensive information on the therapeutics under development for Mammary Ductal Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mammary Ductal Carcinoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mammary Ductal Carcinoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mammary Ductal Carcinoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mammary Ductal Carcinoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mammary Ductal Carcinoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Atossa Therapeutics IncCompugen Ltd
F. Hoffmann-La Roche Ltd
ImmunoRestoration Inc
Marker Therapeutics Inc
Pfizer Inc
SELLAS Life Sciences Group Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mammary Ductal Carcinoma reports